Charles Reninger, MD
Medical Oncology · Camp Hill, PANPI 1912969585
Payments from drug & device makers
Across 44 payments — averaging $58.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Foundation Medicine, Inc.$130
- Johnson & Johnson$118
- Intera Oncology, Inc$86
- E.r. Squibb & Sons, L.L.C.$82
- GSK$67
- plus $418 from 18 others
What the payments were for
- Consulting fees$1,66564%
- Food & beverage$74129%
- Education$1767%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 2 | $1,680 |
| Foundation Medicine, Inc. | 3 | $130 |
| Johnson & Johnson(2 entities) | 5 | $118 |
| Intera Oncology, Inc | 1 | $86 |
| E.r. Squibb & Sons, L.L.C. | 6 | $82 |
| GSK | 1 | $67 |
| Pfizer | 4 | $53 |
| Eisai Inc. | 1 | $52 |
| Merck | 3 | $43 |
| AbbVie | 2 | $37 |
| Gilead | 2 | $28 |
| EMD Serono, Inc. | 2 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Boehringer Ingelheim | 1 | $19 |
| Genentech USA, Inc. | 1 | $18 |
| Regeneron Healthcare Solutions, Inc. | 1 | $18 |
| Incyte Corporation | 1 | $17 |
| Novocure Inc. | 1 | $16 |
| Exelixis Inc. | 1 | $15 |
| Novartis | 1 | $12 |
| Seagen Inc. | 1 | $12 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $12 |
| Spectrum Pharmaceuticals Inc. | 1 | $11 |
| Bristol Myers Squibb | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CALQUENCE$1,665
How this compares
$2,583 in reported general payments places this provider in the 35th percentile of 238 medical oncology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CalquenceAcalabrutinib Maleate | 44 | $666,773 |
| ErleadaApalutamide | 44 | $645,595 |
| Abiraterone Acetate | 128 | $386,555 |
| JakafiRuxolitinib Phosphate | 34 | $384,592 |
| CabometyxCabozantinib S-Malate | 18 | $359,884 |
| RevlimidLenalidomide | 17 | $354,733 |
| TasignaNilotinib Hcl | 17 | $334,869 |
| Lenalidomide | 24 | $310,382 |
| VenclextaVenetoclax | 17 | $209,016 |
| XtandiEnzalutamide | 11 | $148,093 |
| EliquisApixaban | 89 | $78,679 |
| XareltoRivaroxaban | 11 | $16,247 |
| Prochlorperazine Maleate | 112 | $1,517 |
| Anastrozole | 29 | $1,486 |
| Dexamethasone | 73 | $1,269 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaCalquence | $1,680 | $666,77344 claims |
| Johnson & JohnsonErleada, Xarelto | $118 | $661,84255 claims |
| Incyte CorporationJakafi | $17 | $384,59234 claims |
| Exelixis Inc.Cabometyx | $15 | $359,88418 claims |
| Bristol Myers SquibbRevlimid | $11 | $354,73317 claims |
| NovartisTasigna | $12 | $334,86917 claims |
| AbbVieVenclexta | $37 | $209,01617 claims |
| Astellas Pharma US IncXtandi | $21 | $148,09311 claims |
| PfizerEliquis | $53 | $78,67989 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 238 medical oncology providers in Pennsylvania.
Other medical oncology in Camp Hill
- Sukhmani PaddaPhiladelphia$25.6M
- Peter O DwyerPhiladelphia$18M
- Margaret von MehrenPhiladelphia$17.4M
- Kim Reiss BinderPhiladelphia$16.9M
- Carl JunePhiladelphia$13M
- Takami SatoPhiladelphia$11.5M
- Vivek NarayanPhiladelphia$10.6M
- Ubaldo Martinez-OutschoornPhiladelphia$10.5M
- Neil PalmisianoPhiladelphia$10.1M
- Anthony OlszanskiPhiladelphia$9.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.